The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).
Image credit: ©Firefighter Montreal – stock.adobe.com
Enzene Biosciences, based out of Pune in India, has announced the launch of ranibizumab, a biosimilar to Lucentis, which is sold under the name Accentrix in India.1-3
The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab) that is used in therapy for neovascular age-related macular degeneration (AMD). It is also the company’s 7th biosimilar following the launch of Bevacizumab for the treatment of metastatic colorectal cancer.1-3
The biosimilar showed comparative clinical efficacy to Lucentis in phase 3 clincial studies and is produced using the company’s “state-of-the-art MAR system” at its plant in Chakan, Pune.1
Himanshu Gadgil, PhD, CEO, Enzene Biosciences said, “Prior to Ranibizumab, our teams have successfully delivered 6 commercial biosimilars and supported our partners with clinical supplies of novel biologic entities (NBE’s), such as monoclonal antibodies (mAbs) and multi-specific molecules."1
Enzene’s Ranibizumab matches competitors in terms of product purity and is designed to bind and inhibit vascular endothelial growth factor (VEGF-A), thereby interrupting the interaction of VEGF with its receptors.1
Enzene is actively progressing with the development of 3 additional biosimilars in various stages and plans to expand into markets like the USA soon.
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
2 Commerce Drive
Cranbury, NJ 08512